Fujifilm Diosynth Biotechnologies? new mammalian cell-culture facility uses primarily single-use technologies.
Fujifilm Diosynth Biotechnologies formally opened its new mammalian cell culture cGMP manufacturing facility in the United Kingdom, the company reported in a press release. The new facility, which was built and commissioned in less than 15 months, is the first facility of its kind in the UK that was purpose-built to use primarily single-use technologies for both upstream and downstream operations. It has initially been commissioned with 200-L and 1000-L bioreactors, with a 2000-L bioreactor planned for 2014. The company is working on its first customer project for the facility.
This new capacity is the latest in a series of investments at both Fujifilm Diosynth Biotechnologies’ UK and Research Triangle Park, NC, US facilities over the past two years. New cell-line development and process-development laboratories have been set up at both sites, and a 1000-L single-use bioreactor was installed at the US facility two years ago to supplement its 2000-L stainless-steel train for the GMP production of mammalian cell-culture biopharmaceuticals.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.